Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial - Motzer, RJ; Escudier, B; George, S (Cancer, 2020)
et al.